Although higher ATP7A levels mediate platinum drugs resistance in different cell lines [50,51], the discrepancies in ATP7A expression have been previously found in ovarian tumors prior and after treatment, thus additional studies are needed to validate this gene as a molecular marker of resistance [50,52]. The gene discussed is ATP7A; the disease is ovarian neoplasm.